From OpenWetWare
Jump to navigationJump to search

File:Bilder Website Neu.jpeg

Home        Contact        Internal        Lab Members        Publications        Research        Talks       

PD Dr. med. Christian A. Gleissner

Original papers

- Erbel, C., Wolf, A., Lasitschka, F., Linden, F., Domschke, G., Akhavanpoor, M., Doesch, A.O., Katus, H.A., Gleissner, C.A. 2015 Prevalence of M4 macrophages within human coronary atherosclerotic plaques is associated with features of plaque instability. Int J Cardiol, 186:219-225.

- Helmschrott, M., Rivinius, R., Ruhparwar, A., Schmack, B., Erbel, C., Gleissner, C.A., Akhavanpoor, M., Frankenstein, L., Ehlermann, P., Bruckner, T., Katus, H.A., Doesch, A.O. 2015. Advantageous effects of immunosuppression with tacrolimus in comparison with cyclosporine A regarding renal function in patients after heart transplantation. Drug Des Devel Ther, 9:1217-24.

- Rivinius, R., Helmschrott, M., Ruhparwar, A., Schmack, B., Klein, B., Erbel, C., Gleissner, C.A., Akhavanpoor, M., Frankenstein, L., Darche, F.F., Thomas, D., Ehlermann, P., Bruckner, T., Katus, H.A., Doesch, A.O. 2014. Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy. Drug Des Devel Ther, 9:93-102.

- Akhavanpoor, M.*, Gleissner, C.A.*, Gorbatsch, S., Doesch, A.O., Akhavanpoor. H., Wangler, S., Jahn, F., Lasitschka, F., Katus, H.A., Erbel, C. 2014. CCL19 and CCL21 modulate the inflammatory milieu in atherosclerotic lesions. Drug Des Devel Ther, 8:2359-71. * Equal contribution.

- Erbel, C., Akhavanpoor, M., Okuyucu, D., Wangler, S., Dietz, A., Zhao, L., Stellos, K., Little, K.M., Lasitschka, F:, Doesch, A., Hakimi, M., Dengler, T.J., Giese, T., Blessing, E., Katus, H.A., Gleissner, C.A. 2014. IL-17A influences essential functions of the monocyte / macrophage lineage and is involved in advanced murine and human atherosclerosis. J Immunol, 193:4344-55.

- Helmschrott, M., Beckendorf J., Akyol, C., Ruhparwar, A., Schmack, B., Erbel, C., Gleissner, C.A., Akhavanpoor M, Ehlermann, P., Bruckner, T., Katus, H.A., Doesch, A.O. 2014. Superior rejection profile during the first 24 months after heart transplantation under tacrolimus as baseline immunosuppressive regimen. Drug Des Devel Ther, 8:1307-14.

- Gleissner, C.A., Erbel, C., Haeussler, J., Akhavanpoor, M., Domschke, G., Linden, F., Doesch, A.O., Conradson, G., Buss, S.J., Hofmann, N.P., Gitsioudis, G., Katus, H.A. Korosoglou, G. 2014. Low levels of natural IgM antibodies against phosphorylcholine are independently associated with vascular remodeling in patients with coronary artery disease. Clin Res Cardiol, in press.

- Doesch, A.O., Zhao, L., Gleissner, C.A., Akhavanpoor, M., Rohde, D., Okuyucu, D., Hakimi, M., Dengler, T.J., Katus, H.A., Erbel, C. 2014. Inhibition of B7-1 (CD80) by RhuDex(®) reduces lipopolysaccharide-mediated inflammation in human atherosclerotic lesions. Drug Des Devel Ther, 8:447-57.

- Erbel, C., Okuyucu, D., Akhavanpoor, M., Zhao, L., Wangler, S., Hakimi, M., Doesch, A., Dengler, T.J., Katus, H.A., Gleissner, C.A. 2014. A human ex vivo atherosclerotic plaque model to study lesion biology. J Vis Exp, (87).

- Shaked, I., Hanna, D.B., Gleißner, C., Marsh, B., Plants, J., Tracy, D., Anastos, K., Cohen, M., Golub, E.T., Karim, R., Lazar, J., Prasad, V., Tien, P.C., Young, M.A., Landay, A.L., Kaplan, R.C., Ley, K. 2014. Macrophage inflammatory markers are associated with subclinical carotid artery disease in women with human immunodeficiency virus or hepatitis C virus infection. Arterioscler Thromb Vasc Biol, 34(5):1085-92.

- Erbel, C., Tyka, M., Helmes, C.M., Akhavanpoor, M., Rupp, G., Domschke, G., Linden, F., Wolf, A., Doesch, A., Lasitschka, F., Katus, H.A., Gleissner, C.A. 2014. CXCL4-induced plaque macrophages can be specifically identified by co-expression of MMP7+S100A8+ in vitro and in vivo. Innate Immunity, [Epub ahead of print]

- Kraeuter, M., Helmschrott, M., Erbel, C., Gleissner, C.A., Frankenstein, L., Schmack, B., Ruhparwar, A., Ehlermann, P., Katus, H.A., Doesch, A.O. 2013. Conversion to generic cyclosporine A in stable chronic patients after heart transplantation. Drug Des Devel Ther, 7:1421-6.

- Cornu, C., Dufays, C., Gaillard, S., Gueyffier, F., Redonnet, M., Sebbag, L., Roussoulières, A., Gleissner, C.A., Groetzner, J., Lehmkuhl, H.B., Potena, L., Gullestad, L., Cantarovich, M., Boissonnat, P. Impact of the Reduction of Calcineurin Inhibitors on Renal Function in Heart Transplant Patients: A Systematic Review and Meta-Analysis. 2013. Br J Clin Pharmacol, [Epub ahead of print]

- Kraeuter, M., Helmschrott, M., Erbel, C., Gleissner ,C.A., Frankenstein, L., Schmack, B., Ruhparwar, A., Ehlermann, P., Katus, H.A., Doesch, A.O. 2013. Conversion to generic cyclosporine A in stable chronic patients after heart transplantation. Drug Des Devel Ther, 7:1421-6.

- Doesch, A.O., Mueller, S., Erbel, C., Gleissner, C.A., Frankenstein, L., Hardt, S., Ruhparwar, A., Ehlermann, P., Dengler, T., Katus, H.A. 2013. Heart rate reduction for 36 months with ivabradine reduces left ventricular mass in cardiac allograft recipients: a long-term follow-up study. Drug Des Devel Ther, 2013 7:1323-8.

- Erbel, C., Rupp, G., Helmes, C.M., Tyka, M., Linden, F., Doesch, A.O., Katus, H.A., Gleissner ,C.A. 2013. An in vitro model to study heterogeneity of human macrophage differentiation and polarization. J Vis Exp. (76).

- Gueler, I., Mueller, S., Helmschrott, M., Oeing, C.U., Erbel, C., Frankenstein, L., Gleissner, C., Ruhpawar, A., Ehlermann, P., Dengler, T.J., Katus, H.A., Doesch, A.O. 2013. Effects of vildagliptin (Galvus ®) therapy in patients with type 2 diabetes mellitus after heart transplantation. Drug Des Devel Ther, 7:297-303.

- Erbel, C., Taskin, R., Doesch, A., Dengler, T.J., Wangler, S., Akhavanpoor, M., Ruhpawar, A., Giannitsis, E., Katus, H.A., Gleissner, C.A. 2013. High sensitive troponin T measurements early after heart transplantation predict shot and long term survival. Transplantation, 26(3):267-72.

- Doesch, A.O., Repp, J., Hofmann, N., Erbel, C. Frankenstein, L., Gleissner, C.A., Schmidt, C., Ruhpawar, A., Zugck, C., Schnitzler, P., Ehlermann, P., Dengler, T.J., Katus, H.A. 2012. Effects of oral Valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients. Drug Des Devel Ther, 6:289-95.

- Korosoglou, G., Gleissner, C.A., Giannitsis, E., Katus, H.A. 2012. Subclinical atherosclerosis and chronic troponin elevation: the voice of silence in diabetics. J Am Coll Cardiol, 60(2):167-8.

- Erbel, C., Achenbach, J., Dengler, T.J., Lasitschka, F., Gleissner, C.A., Bea, F., Katus, H.A., Szabo, G. 2011. PARP inhibition in atherosclerosis and its effects on dendritic cells, T cells and auto-antibody levels. Eur J Med Res, 16(8):367-74.

- Erbel, C., Dengler, T.J., Wangler, S., Bea, F. Wambsganss, N., Hakimi, M., Böckler, D., Katus, H.A., Gleissner, C.A. 2010. Expression of IL-17A in human atherosclerotic lesions is associated with increased inflammation and plaque vulnerability. Basic Res Cardiol, 106(1), 125-34.

- Gleissner, C.A., Little, K.M., Ley, K. 2010. CXCL4 induces a unique transcriptome in monocyte-derived macrophages. J Immunol, 184 (9), 4810-8.

- Schulz, C., Heuschen, N.V., Fröhlich, T., Lorenz, M., Pfeiler, S., Gleissner, C.A., Kremmer, E., Kessler, M., Khandogau A.G., Engelmann, B., Ley, K., Massberg, S., Arnold, G.J. 2010. Identification of novel downstream targets of platelet glycoprotein VI activation. Blood, 115(20):4102-10.

- Gleissner, C.A., Shaked, I., Erbel, C., Böckler, D., Katus, H.A., Ley, K. 2010. CXCL4 induces CD163- macrophages: Functional implication in atherosclerosis. Circ Res, 106(1):203-11.

- Konstandin, M.H., Doesch, A., Ammon, K., Wabnitz, G.H., Gleissner, C.A., Koch, A., Remppis, A., Katus, H.A., Dengler, T.J. 2008. Ezetimibe effectively lowers LDL-cholesterol in cardiac allograft recipients on stable statin therapy. Clin Transplant, 22(5):639-44.

- Gleissner, C.A., Sanders, J.M., Nadler, J.L., Ley, K. 2007. Upregulation of aldose reductase during foam cell formation as possible link among diabetes, hyperlipidemia and atherosclerosis. Arterioscler Thromb Vasc Biol, 28(6):1137-43.

- Cho, H.J., Shashkin, P., Gleissner, C.A., Dunson, D., Jain, N., Lee, J., Miller, Y., Ley, K. 2007. Induction of dendritic cell-like phenotype in macrophages during foam cell formation. Physiol Genomics, 29(2):149-160.

- Gleissner, C.A., Zastrow, A., Klingenberg, R., Kluger, M.S., Konstandin, M., Celik, S., Haemmerling, S., Shankar, V., Giese, T., Katus, H.A., Dengler, T.J. 2007. IL-10 inhibits endothelium-dependent T-cell costimulation by upregulation of ILT3/4 in human vascular endo-thelial cells. Eur J Immunol, 37(1):177-192.

- Gleissner, C.A., Doesch, A., Ehlermann, P., Koch, A., Sack, F.U., Katus, H.A., and Dengler, T.J. 2006. Cyclosporine withdrawal improves renal function in heart transplant patients on reduced-dose cyclosporine therapy. Am J Transplant, 6(11):2750-2758.

- Gleissner, C.A., Klingenberg, R., Staritz, P., Koch, A., Ehlermann, P., Wiggenhauser, A., and Dengler, T.J. 2006. Role of erythropoietin in anemia after heart transplantation. Int J Cardiol 112(3):341-347.

- Klingenberg, R., Gleissner, C., Koch, A., Schnabel, P.A., Sack, F.U., Zimmermann, R., Katus, H.A., and Dengler, T.J. 2005. Impact of pre-operative diabetes mellitus upon early and late survival after heart transplantation: a possible era effect. J Heart Lung Transplant 24(9):1239-1246.

- Klingenberg, R., Autschbach, F., Gleissner, C., Giese, T., Wambsganss, N., Sommer, N., Richter, G., Katus, H.A., and Dengler, T.J. 2005. Endothelial inducible costimulator ligand expression is increased during human cardiac allograft rejection and regulates endothelial cell-dependent allo-activation of CD8+ T cells in vitro. Eur J Immunol 35(6):1712-1721.

- Klingenberg, R., Koch, A., Gleissner, C., Schnabel, P.A., Haass, M., Remppis, A., Katus, H.A., and Dengler, T.J. 2005. Determinants of B-type natriuretic peptide plasma levels in the chronic phase after heart transplantation. Transpl Int 18(2):169-176.

- Gleissner, C.A., Murat, A., Schafer, S., Klingenberg, R., Koch, A., Remppis, A., Zimmermann, R., Katus, H.A., and Dengler, T.J. 2004. Reduced hemoglobin after heart transplantation is no independent risk factor for survival but is associated closely with impaired renal function. Transplantation 77(5):710-717.

- Gleissner, C.A., Klingenberg, R., Nottmeyer, W., Zipfel, S., Sack, F.U., Schnabel, P.A., Haass, M., and Dengler, T.J. 2003. Diagnostic efficiency of rejection monitoring after heart transplantation with cardiac troponin T is improved in specific patient subgroups. Clin Transplant 17(3):284-291.

- Gleissner, C.A., Zehelein, J., Sack, F.U., Schnabel, P., Haass, M., and Dengler, T.J. 2002. Extended experience and subgroup analysis using cardiac troponin T for rejection monitoring after heart transplantation. Transplant Proc 34(6):2178-2180.

Reviews and Editorials

- Linden, F., Domschke, G., Erbel, C., Akhavanpoor, M., Katus, H.A., Gleissner. C.A. 2014. Inflammation in coronary atherosclerosis – from molecular biology to clinical application. Front Physiol, in press.

- Akhavanpoor M., Wangler S., Gleissner C.A., Korosoglou G., Katus H.A., Erbel C. 2014. Adventitial inflammation and its interaction with intimal atherosclerotic lesions. Front Physiol, 5:296.

- Gleissner, C.A. 2012. Platelet-derived chemokines in atherosclerosis – what´s new? Curr Vasc Pharmacol, 10(5):563-9.

- Gleissner, C.A. 2012. Macrophage phenotype modulation by platelet factor-4 in vascular disease. Front Vasc Biol, 2012;3:1.

- Sperandio, M., Gleissner, C.A., Ley, K. 2009. Glycosylation in immune cell trafficking. Immunol Rev, 230(1):97-113.

- Gleissner, C.A., Dengler T.J. 2009. Induction of ILT expression on non-professional APC: Clinical Applications. Human Immunol, 70(5):357-9.

- Gleissner, C.A., von Hundelshausen, P., Ley, K. 2008. Chemokines and platelet functions in vascular disease. Arterioscler Thromb Vasc Biol, 28(11):1920-1927.

- Gleissner, C.A., Galkina E., Nadler J.L., Ley, K. 2008. Mechanisms by which diabetes increases cardiovascular disease. Drug Discovery Today: Disease Mechanisms, 4(3):131-140.

- Gleissner, C.A., Ley, K. 2007. CXCL4 in atherosclerosis: possible role in monocyte arrest and macrophage foam cell formation. Thromb Haemost, 98(5):917-918.

- Gleissner, C.A., Leitinger, N., Ley, K. 2007. Effects of native and modified low density lipoprotein on monocyte recruitment in atherosclerosis. Hypertension, 50(2):276-283.

- Dengler, T.J., Gleissner, C.A., Klingenberg, R., Sack, F.-U., Schnabel, P.A., Katus, H.A. 2007. Biomarkers after heart transplantation – non-genomic. Heart Failure Clinics, 3(1):69-81.

Book chapters

- Gleissner, C.A., Erbel C., Katus, H.A. CXCL4 (Platelet factor-4) inhibits foam cell formation in human macrophages. In: Annual Meeting of the German Atherosclerosis Society 2011. ISBN 978-3-936423-09-9.

- Gleissner, C.A., Erbel, C. CXCL4-induced macrophages: A novel therapeutic target in human atherosclerosis? In: Atherogenesis, InTech – Open Access Publisher, Rijeka, Croatia, 2011.ISBN 978-953-307-992-9.

- Gleissner, C.A. Understanding macrophage heterogeneity in human atherosclerosis – the key to treating cardiovascular disease? In: Research Advances in circulation research, Global Research Network, Kerala, India, 2011.